MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
Wenfeng Fang, Huaqiang Zhou, Jiayi Shen, Jianwen Li, Yaxiong Zhang, Shaodong Hong, Li Zhang
Abstract
The revolutionary immune checkpoint inhibitors (ICI) treatment has been a landmark of cancer therapy, with long-term survival benefit in advanced cancer patients reported.1 In another aspect, relatively low response rates and hyperprogression remain to be solved in immunotherapy.2 3 There have been some known biomarkers for the prediction of ICI efficacy, such as programmed death-ligand 1 expression, tumour mutational burden (TMB), microsatellite instability (MSI) and mismatch-repair deficiency.
Topics & Concepts
Microsatellite instabilityImmunotherapyCancerImmune checkpointImmune systemMdm2OncologyCancer researchDNA mismatch repairMedicineCancer immunotherapyInternal medicineBiologyImmunologyGeneticsApoptosisMicrosatelliteColorectal cancerGeneAlleleCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsPancreatic and Hepatic Oncology Research